Lee Philina 4

Accession 0001415889-24-020928

CIK 0001597264other

View on SEC.gov Company Profile

Filed

Aug 6, 8:00 PM ET

Accepted

Aug 7, 5:06 PM ET

Size

31.3 KB

Accession

0001415889-24-020928

Insider Transaction Report

Form 4

Period: 2024-08-05

Blueprint Medicines CorpBPMC

Lee Philina

CHIEF COMMERCIAL OFFICER

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−5,011→ 0 total
Exercise: $81.44Exp: 2028-02-16→ Common Stock (5,011 underlying)
Exercise/Conversion
Common Stock
2024-08-05$81.44/sh+5,011$408,096→ 40,939 total
Exercise/Conversion
Common Stock
2024-08-05$36.05/sh+157$5,660→ 34,886 total
Exercise/Conversion
Common Stock
2024-08-05$54.13/sh+8,450$457,399→ 53,720 total
Sale
Common Stock
2024-08-05$93.19/sh−41,913$3,905,872→ 34,729 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−1,042→ 0 total
Exercise: $51.06Exp: 2027-07-03→ Common Stock (1,042 underlying)
Exercise/Conversion
Common Stock
2024-08-05$51.06/sh+1,042$53,205→ 35,928 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−4,331→ 20,669 total
Exercise: $43.15Exp: 2033-03-01→ Common Stock (4,331 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−8,450→ 0 total
Exercise: $54.13Exp: 2030-03-01→ Common Stock (8,450 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−157→ 0 total
Exercise: $36.05Exp: 2027-02-16→ Common Stock (157 underlying)
Exercise/Conversion
Common Stock
2024-08-05$43.15/sh+4,331$186,883→ 45,270 total
Exercise/Conversion
Common Stock
2024-08-05$86.60/sh+12,350$1,069,510→ 76,642 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−10,572→ 6,928 total
Exercise: $61.31Exp: 2032-03-01→ Common Stock (10,572 underlying)
Exercise/Conversion
Common Stock
2024-08-05$61.31/sh+10,572$648,169→ 64,292 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-08-05−12,350→ 0 total
Exercise: $86.60Exp: 2029-03-01→ Common Stock (12,350 underlying)

Footnotes (8)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $93.00 to $93.835 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F2]This option was granted on February 16, 2017 and is fully vested as of the transaction date.
[F3]This option was granted on July 3, 2017 and is fully vested as of the transaction date.
[F4]This option was granted on February 16, 2018 and is fully vested as of the transaction date.
[F5]This option was granted on March 1, 2023. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter.
[F6]This option was granted on March 1, 2020 and is fully vested as of the transaction date.
[F7]This option was granted on March 1, 2022. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter.
[F8]This option was granted on March 1, 2019 and is fully vested as of the transaction date.

Documents

1 file

4
form4-08072024_090858.xmlPrimary

Issuer

Blueprint Medicines Corp

CIK 0001597264

→

Entity typeother

Related Parties

filerCIK 0001845080

Filing Metadata

Form type: 4
Filed: Aug 6, 8:00 PM ET
Accepted: Aug 7, 5:06 PM ET
Size: 31.3 KB

View on SEC.gov